CM
NDRM

Crestline Management’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Crestline Management’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-50,468
Closed -$1.51M – 200
2017
Q2 		$1.51M Buy
50,468
+32,468
+180% +$841K 0.2% 56
2017
Q1 		$478K Buy
+18,000
New +$446K 0.09% 88

Other funds holding NDRM

AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
SAM
Sandell Asset Management New York $179M AUM 65.55% 1-Year Est. Return
OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
CFIC
City Financial Investment Company London, United Kingdom $562M AUM 5.93% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Crestline Management's NDRM Position: Q3 2017 in Review

Crestline Management sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q3 2017, closing a stake of 50,468 shares — an estimated $1.51M sold.

Crestline Management first reported a position in NDRM in Q1 2017 and held it in 2 quarters. The position peaked at $1.51M in Q2 2017. 81 funds tracked by Wall St. Rank hold NDRM as of Q3 2017.

  • Crestline Management reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q3 2017 after selling out during the quarter.
  • Crestline Management sold 50,468 NeuroDerm Ltd. Ordinary Shares shares in Q3 2017, an estimated $1.51M.
  • Crestline Management first reported a position in NeuroDerm Ltd. Ordinary Shares in Q1 2017 and held it in 2 quarters.
  • Crestline Management's NeuroDerm Ltd. Ordinary Shares position peaked at $1.51M in Q2 2017.
  • 81 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q3 2017.

Based on Crestline Management's 13F filing for Q3 2017, filed 14 Nov 2017.